share_log

Exicure | DEF 14A: Definitive information statements

Exicure | DEF 14A: Definitive information statements

Exicure | DEF 14A：股東委託書決議
美股SEC公告 ·  07/30 17:11
Moomoo AI 已提取核心訊息
Exicure, Inc., a biotechnology company, has announced a Special Meeting of Stockholders to be held virtually on August 15, 2024. The primary agenda for the meeting is to seek approval for a reverse stock split of the company's common stock at a ratio ranging from 1-for-2 to 1-for-15, as determined by the Board of Directors. This strategic move aims to comply with Nasdaq's minimum bid price requirement and improve the stock's marketability. The company's common stock has been under the required $1.00 per share, prompting a potential delisting from Nasdaq. Exicure received a notification from Nasdaq on September 13, 2023, and was given until September 9, 2024, to regain compliance. The reverse stock split is intended to increase the per-share price to...Show More
Exicure, Inc., a biotechnology company, has announced a Special Meeting of Stockholders to be held virtually on August 15, 2024. The primary agenda for the meeting is to seek approval for a reverse stock split of the company's common stock at a ratio ranging from 1-for-2 to 1-for-15, as determined by the Board of Directors. This strategic move aims to comply with Nasdaq's minimum bid price requirement and improve the stock's marketability. The company's common stock has been under the required $1.00 per share, prompting a potential delisting from Nasdaq. Exicure received a notification from Nasdaq on September 13, 2023, and was given until September 9, 2024, to regain compliance. The reverse stock split is intended to increase the per-share price to meet Nasdaq's listing standards. Stockholders of record as of July 26, 2024, are eligible to vote at the meeting. The Board recommends voting in favor of the reverse stock split. The meeting will also address any other business that may properly come before it. Voting can be done electronically during the meeting or by proxy via telephone, internet, or mail as detailed in the Proxy Statement.
生物技術公司Exicure， Inc.宣佈將於2024年8月15日以虛擬方式舉行股東特別會議。會議的主要議程是徵得董事會批准，並以1比2至1比15的比例對公司普通股進行反向股票分割。此項戰略舉措旨在遵守納斯達克的最低買盤價格要求並提高股票的流通性。公司的普通股未達到納斯達克要求的每股1美元，可能會導致被納斯達克除牌。Exicure於2023年9月13日收到納斯達克的通知，並被賦予至2024年9月9日恢復遵從性的時間。反向股票分割旨在增加每股價格以符合納斯達克的上市標準。截至2024年7月26日的記錄股東有權投票參加會議。董事會建議投票支持反向股票分割。會議還將討論可能到達的任何其他業務。可以在會議期間通過電子投票或通過電話、互聯網或郵件代理進行投票，具體請參閱委託聲明。
生物技術公司Exicure， Inc.宣佈將於2024年8月15日以虛擬方式舉行股東特別會議。會議的主要議程是徵得董事會批准，並以1比2至1比15的比例對公司普通股進行反向股票分割。此項戰略舉措旨在遵守納斯達克的最低買盤價格要求並提高股票的流通性。公司的普通股未達到納斯達克要求的每股1美元，可能會導致被納斯達克除牌。Exicure於2023年9月13日收到納斯達克的通知，並被賦予至2024年9月9日恢復遵從性的時間。反向股票分割旨在增加每股價格以符合納斯達克的上市標準。截至2024年7月26日的記錄股東有權投票參加會議。董事會建議投票支持反向股票分割。會議還將討論可能到達的任何其他業務。可以在會議期間通過電子投票或通過電話、互聯網或郵件代理進行投票，具體請參閱委託聲明。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息